Management of relapsed chronic lymphocytic leukemia (notice n° 174742)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01450cam a2200157 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112040004.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Tomowiak, Cécile |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Management of relapsed chronic lymphocytic leukemia |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 83 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The last 10 years have seen a number of changes that have made a tremendous impact in the management of patients with chronic lymphocytic leukemia (CLL): A better understanding of the biology of the disease, characterization of sub-populations at risk, and the development of oral therapies. Currently, Bruton’s tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 inhibitor (BCL2i) venetoclax are standard first-line and relapse treatments, as monotherapy or in combination. However, treatment sequences (continuous or fixed-duration) and optimal combinations have yet to be defined. In this review, we will focus on the management of relapsed patients. We will discuss the important elements to consider when choosing treatment and, more generally, in the strategy for treatment lines. Recent advances in this disease represent significant progress and raise new questions about how available drugs should be used and how we can continue to improve CLL treatment. |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 30 | Special Issue 1 | 2024-06-02 | p. 19-27 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-hematologie-2024-Supp1-page-19?lang=en">https://shs.cairn.info/journal-hematologie-2024-Supp1-page-19?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux